Advanced glycation end-products: new markers of renal dysfunction in patients with chronic heart failure

被引:1
作者
Raposeiras-Roubin, Sergio [2 ]
Rodino-Janeiro, Bruno K. [1 ]
Grigorian-Shamagian, Lilian [2 ,3 ]
Moure-Gonzalez, Maria [2 ]
Seoane-Blanco, Ana [2 ]
Varela-Roman, Alfonso [2 ]
Alvarez, Ezequiel [1 ,4 ]
Gonzalez-Juanatey, Jose R. [1 ,2 ,4 ]
机构
[1] Inst Invest Sanitarias Santiago de Compostela, Lab Invest 6, Santiago De Compostela, Spain
[2] Hosp Clin Univ Santiago de Compostela, Serv Cardiol, Santiago De Compostela, Spain
[3] Complejo Hosp Univ Vigo, Serv Cardiol, Vigo, Spain
[4] Fac Med & Odontol, Dept Med, Santiago De Compostela, Spain
来源
MEDICINA CLINICA | 2011年 / 136卷 / 12期
关键词
Advanced glycation end-products; Chronic heart failure; Kidney failure; Hidden kidney disease; PROGNOSTIC VALUE; DISEASE; RISK; SERUM; AGES; ACCUMULATION; ENDPRODUCTS; MORTALITY;
D O I
10.1016/j.medcli.2010.06.030
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and objectives: Advanced glycation end-products (AGE) are implicated in the physiopathology and prognosis of heart failure (HF) and they accumulate in situations such as kidney failure (KF). Our objective was to analyze the relation between AGE and KF in patients with chronic HF. Materials and methods: 102 consecutive patients of our medical center were included. Clinical and analytical data were obtained, with measurement of glycated haemoglobin, brain natriuretic peptide, cystatin C and fluorescent AGE. Glomerular filtration rate (GFR) was estimated for each patient. Results: 40.2% of patients presented GFR < 60 mL/min/1.73m(2) and 11.7% had hidden kidney disease (HKD). AGE correlated positively with creatinine (r = 0.685, p < 0.001) and cystatin C (r = 0.682, p < 0.001) and negatively with GFR (r = -0.720, p < 0.001). Medium value of fluorescent AGE in patients with KF was higher than those without KF (83.4 [3.3] URF vs 56.8 [2.1] URF, p < 0.001). With regard to the diagnostic value for HKD, fluorescent AGE presented an area under the ROC curve higher than other parameters for KD such as cystatin C. In the multivariate analysis, fluorescent AGE were an independent biomarker of KD (OR 1.060; 95% CI 1.024-1.097; p = 0.001). Conclusions: AGE act as a biomarker of KD in patients with chronic HP, both diabetics and non diabetics, being better than cystatin C in the detection of HKD. (C) 2010 Elsevier Espana, S.L. All rights
引用
收藏
页码:513 / 521
页数:9
相关论文
共 33 条
  • [2] [Anonymous], 2002, Am J Kidney Dis, V39, P51
  • [3] SCreening for Occult REnal Disease (SCORED) - A simple prediction model for chronic kidney disease
    Bang, Heejung
    Vupputuri, Suma
    Shoham, David A.
    Klemmer, Philip J.
    Falk, Ronald J.
    Mazumdar, Madhu
    Gipson, Debbie
    Colindres, Romulo E.
    Kshirsagar, Abhijit V.
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2007, 167 (04) : 374 - 381
  • [4] Advanced glycation end products regulate extracellular matrix protein and protease expression by human glomerular mesangial cells
    Berrou, J.
    Tostivint, I.
    Verrecchia, F.
    Berthier, C.
    Boulanger, E.
    Mauviel, A.
    Marti, H. P.
    Wautier, M. P.
    Wautier, J. L.
    Rondeau, E.
    Hertig, A.
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2009, 23 (04) : 513 - 520
  • [5] Negative consequences of glycation
    Brownlee, M
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 2000, 49 (02): : 9 - 13
  • [6] Oxidative stress and advanced glycation in diabetic nephropathy
    Coughlan, Melinda T.
    Mibus, Amy L.
    Forbes, Josephine M.
    [J]. MAILLARD REACTION: RECENT ADVANCES IN FOOD AND BIOMEDICAL SCIENCES, 2008, 1126 : 190 - 193
  • [7] Combination therapy with the advanced glycation end product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: Synergy or redundancy?
    Coughlan, Melinda T.
    Thallas-Bonke, Vicki
    Pete, Josefa
    Long, David M.
    Gasser, Anna
    Tong, David C. K.
    Arnstein, Maryann
    Thorpe, Suzanne R.
    Cooper, Mark E.
    Forbes, Josephine M.
    [J]. ENDOCRINOLOGY, 2007, 148 (02) : 886 - 895
  • [8] ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)
    Dickstein, Kenneth
    Cohen-Solal, Alain
    Filippatos, Gerasimos
    McMurray, John J. V.
    Ponikowski, Piotr
    Poole-Wilson, Philip Alexander
    Stromberg, Anna
    van Veldhuisen, Dirk J.
    Atar, Dan
    Hoes, Amo W.
    Keren, Andre
    Mebazaa, Alexandre
    Nieminen, Markku
    Priori, Silvia Gluliana
    Swedberg, Karl
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2008, 10 (10) : 933 - 989
  • [9] Cystatin C Provides More Information Than Other Renal Function Parameters for Stratifying Risk in Patients With Acute Coronary Syndrome
    Garcia Acuna, Jose M.
    Gonzalez-Babarro, Eva
    Grigorian Shamagian, Lilian
    Pena-Gil, Carlos
    Vidal Perez, Rafael
    Lopez-Lago, Ana M.
    Gutierrez Feijoo, Mario
    Gonzalez-Juanatey, Jose R.
    [J]. REVISTA ESPANOLA DE CARDIOLOGIA, 2009, 62 (05): : 510 - 519
  • [10] What is the influence of renal function on the prognostic value of advanced glycation end-products and sRAGE in heart failure?
    Hartog, Jasper W. L.
    Willemsen, Suzan
    Voors, Adriaan A.
    [J]. JOURNAL OF CARDIAC FAILURE, 2008, 14 (07) : 626 - 626